{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:16:26Z","timestamp":1762506986093,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.urolonc.2016.11.014","type":"journal-article","created":{"date-parts":[[2017,1,5]],"date-time":"2017-01-05T11:16:59Z","timestamp":1483615019000},"page":"208-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Characterizing intermediate-risk non\u2013muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy"],"prefix":"10.1016","volume":"35","author":[{"given":"Kazuhiro","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Yanai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nozomi","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohiko","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.11.014_bib1","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib2","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"year":"2016","series-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","author":"Chang","key":"10.1016\/j.urolonc.2016.11.014_bib3"},{"year":"2016","series-title":"Clinical practice guidelines in oncology: bladder cancer. Version 2","author":"National Comprehensive Cancer Network","key":"10.1016\/j.urolonc.2016.11.014_bib4"},{"year":"2016","series-title":"Guidelines on non-muscle-invasive bladder cancer","author":"Babjuk","key":"10.1016\/j.urolonc.2016.11.014_bib5"},{"key":"10.1016\/j.urolonc.2016.11.014_bib6","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","article-title":"Management of stage T1 tumors of the bladder: International Consensus Panel","volume":"66","author":"Nieder","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.11.014_bib8","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib9","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.11.014_bib11","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib13","doi-asserted-by":"crossref","first-page":"E508","DOI":"10.1111\/j.1464-410X.2012.11194.x","article-title":"Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Gu\u00e9rin relapsing non-muscle-invasive bladder cancer","volume":"110","author":"Matsumoto","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.11.014_bib14","doi-asserted-by":"crossref","first-page":"E216","DOI":"10.1111\/j.1464-410X.2011.10894.x","article-title":"Prognostic significance of bacillus Calmette-Gu\u00e9rin failure classification in non-muscle-invasive bladder cancer","volume":"110","author":"Shirakawa","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2016.11.014_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2013.09.049","article-title":"Bacillus Calmette-Gu\u00e9rin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist\u05f3s failure to detect urothelial carcinoma of the upper urinary tract and urethra","volume":"65","author":"Giannarini","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib16","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib17","doi-asserted-by":"crossref","first-page":"E411","DOI":"10.5489\/cuaj.2818","article-title":"The role of single instillation chemotherapy in patients who receive subsequent bacillus Calmette-Gu\u00e9rin: a retrospective single centre study, and systematic review of the literature","volume":"9","author":"Matsumoto","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urolonc.2016.11.014_bib18","doi-asserted-by":"crossref","first-page":"e47199","DOI":"10.1371\/journal.pone.0047199","article-title":"The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2016.11.014_bib19","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.juro.2013.08.022","article-title":"The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Gu\u00e9rin","volume":"191","author":"Sfakianos","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1442-2042.2010.02486.x","article-title":"Evidence-based clinical practice guidelines for bladder cancer (summary\u2014JUA 2009 Edition)","volume":"17","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2016.11.014_bib21","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916304021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143916304021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:09:20Z","timestamp":1761041360000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143916304021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1078143916304021"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.11.014","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterizing intermediate-risk non\u2013muscle-invasive bladder cancer: Implications for the definition of intermediate risk and treatment strategy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}